Mr. Onaitis brings a wealth of public company general counsel experience to Cidara. Prior to joining Cidara, Mr. Onaitis was General Counsel and Secretary of Ignyta. Previously, he was General Counsel and Secretary of Trius Therapeutics, Inc. from May 2013 through its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Following the acquisition Mr. Onaitis remained with Cubist assisting with the integration through December 2013. Mr. Onaitis was Senior Vice President, General Counsel and Secretary at Somaxon Pharmaceuticals from May 2006 through Somaxon’s acquisition by Pernix Therapeutics Holdings in March 2013. Prior to Somaxon, Mr. Onaitis served as Associate General Counsel at Biogen Idec, as Director, Legal Affairs at Elan Corporation, and in private practice specializing in corporate and commercial law. Mr. Onaitis is a director of SNP Bio, Inc. Mr. Onaitis holds a J.D. from Stanford Law School and a B.S. in mechanical engineering from Carnegie Mellon University.